SPYPHARMA
Board
1 director, no change since 2024Manager, permanent representative
current term since 25-08-2022
listed in the 2025 annual accounts, filed on 30-08-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “Article 12bis. La compétence de l’organe d’administration Chaque administrateur représente la société à l'égard des tiers et en justice…”deed of 08-09-2022
Permanent representatives 1
Mandates through the years
3 names, the dashed line is todayManager
Director
Director (not named in the articles)
BoardEarlierend not dated
Mandates as a list
-
- Manager, appointed by deed of 13-05-2016, still in office
-
- Director, appointed by deed of 15-10-2024, no longer listed in the 2025 annual accounts
-
- Director (not named in the articles), appointed by deed of 08-09-2022, no longer listed in the 2025 annual accounts
Control
Shareholder
Equity €1.5m
Profit €178,455 in 2025 (profit €46,083 in 2024)
Checked score
Source: own accounts 2023
share not stated
This company
SPYPHARMA
Equity -€157,859
Loss €147,773 in 2025
Capital
- Contribution
- €18,592.01
- Source
- deed of 08-09-2022
Articles of association
deed of 08-09-2022 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- At least 1 director
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last Friday of May at 20:00